Literature DB >> 3282674

The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein.

M Koenig1, A P Monaco, L M Kunkel.   

Abstract

The complete sequence of the human Duchenne muscular dystrophy (DMD) cDNA has been determined. The 3685 encoded amino acids of the protein product, dystrophin, can be separated into four domains. The 240 amino acid N-terminal domain has been shown to be conserved with the actin-binding domain of alpha-actinin. A large second domain is predicted to be rod-shaped and formed by the succession of 25 triple-helical segments similar to the repeat domains of spectrin. The repeat segment is followed by a cysteine-rich segment that is similar in part to the entire COOH domain of the Dictyostelium alpha-actinin, while the 420 amino acid C-terminal domain of dystrophin does not show any similarity to previously reported proteins. The functional significance of some of the domains is addressed relative to the phenotypic characteristics of some Becker muscular dystrophy patients. Dystrophin shares many features with the cytoskeletal protein spectrin and alpha-actinin and is a large structural protein that is likely to adopt a rod shape about 150 nm in length.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282674     DOI: 10.1016/0092-8674(88)90383-2

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  435 in total

1.  short stop is allelic to kakapo, and encodes rod-like cytoskeletal-associated proteins required for axon extension.

Authors:  S Lee; K L Harris; P M Whitington; P A Kolodziej
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

Review 2.  Syntrophins entangled in cytoskeletal meshwork: Helping to hold it all together.

Authors:  Sahar S Bhat; Roshia Ali; Firdous A Khanday
Journal:  Cell Prolif       Date:  2018-12-04       Impact factor: 6.831

3.  Disease-causing missense mutations in actin binding domain 1 of dystrophin induce thermodynamic instability and protein aggregation.

Authors:  Davin M Henderson; Ann Lee; James M Ervasti
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

4.  Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.

Authors:  Paul S Sharp; Hema Bye-a-Jee; Dominic J Wells
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

5.  Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys.

Authors:  Utkarsh J Dang; Michael Ziemba; Paula R Clemens; Yetrib Hathout; Laurie S Conklin; Eric P Hoffman
Journal:  Hum Mol Genet       Date:  2020-08-29       Impact factor: 6.150

6.  ERG phenotype of a dystrophin mutation in heterozygous female carriers of Duchenne muscular dystrophy.

Authors:  K M Fitzgerald; G W Cibis; A H Gettel; R Rinaldi; D J Harris; R A White
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

7.  Desmuslin, an intermediate filament protein that interacts with alpha -dystrobrevin and desmin.

Authors:  Y Mizuno; T G Thompson; J R Guyon; H G Lidov; M Brosius; M Imamura; E Ozawa; S C Watkins; L M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

8.  Truncated dystrophins can influence neuromuscular synapse structure.

Authors:  Glen B Banks; Jeffrey S Chamberlain; Stanley C Froehner
Journal:  Mol Cell Neurosci       Date:  2009-01-08       Impact factor: 4.314

9.  Nitric oxide generated by muscle corrects defects in hippocampal neurogenesis and neural differentiation caused by muscular dystrophy.

Authors:  Bo Deng; David Glanzman; James G Tidball
Journal:  J Physiol       Date:  2009-02-23       Impact factor: 5.182

10.  Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.

Authors:  Annemieke Aartsma-Rus; Anneke A M Janson; Wendy E Kaman; Mattie Bremmer-Bout; Gert-Jan B van Ommen; Johan T den Dunnen; Judith C T van Deutekom
Journal:  Am J Hum Genet       Date:  2003-12-16       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.